Correlation of BUB1 and BUB1B with the development and prognosis of endometrial cancer
Authors:
Open Access
- 24 July 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-11
Abstract
This study aimed to evaluate the expression and clinical significance of budding uninhibited by benzimidazole 1 (BUB1) and BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B) in endometrial carcinoma (EC). BUB1 and BUBIB expressions were evaluated by bioinformatics. Protein expression, clinical features, prognosis and immune cell infiltration were explored in 20 EC tumors. siRNA was used to evaluate BUB1 and BUBIB function in EC cells. BUB1 and BUBIB were highly expressed in 26 cancers. BUB1 was associated with overall survival (OS) in eight cancers and disease-free survival in ten; BUB1B was associated with OS in nine cancers and DFS in eleven. BUB1 and BUBIB exhibited high frequencies of gene changes (mainly mutations, > 5%) in cancer. BUB1 was negatively correlated and BUB1B was positively correlated with cancer-associated fibroblasts and endothelial cell infiltration. BUB1 and BUBIB knockdown decreased migration and invasion in EC cells. High BUB1 expression correlated with tumor malignant phenotypes (P < 0.05). High BUB1 mRNA expression reduced OS (P = 0.00036) and recurrence-free survival (P = 0.0011). High BUB1B mRNA expression reduced OS (P = 0.0024). BUB1/BUB1B correlated with activated CD8 + T and CD4 + T cell infiltration. BUB1 and BUBIB are highly expressed and correlated with clinicopathological characteristics in EC. BUB1 and BUBIB are potential prognosis markers and immunotherapy targets.Keywords
Funding Information
- “Master’s Scientific Fund Project of the Education Department of Yunnan Province (2022Y860)
- Dali University research and development Fund (FZ2023YB036)
This publication has 43 references indexed in Scilit:
- The association between the tumor immune microenvironments and clinical outcome in low‐grade, early‐stage endometrial cancer patientsThe Journal of Pathology, 2022
- Identification of key molecular markers in epithelial ovarian cancer by integrated bioinformatics analysisTaiwanese Journal of Obstetrics and Gynecology, 2021
- Mitotic checkpoint defects: en route to cancer and drug resistanceChromosome Research, 2021
- Molecular targeted therapy: Treating cancer with specificityEuropean Journal of Pharmacology, 2018
- USP9X Limits Mitotic Checkpoint Complex Turnover to Strengthen the Spindle Assembly Checkpoint and Guard against Chromosomal InstabilityCell Reports, 2018
- Prevalence of germline mutations in the spindle assembly checkpoint gene BUB1B in individuals with early‐onset colorectal cancerGenes, Chromosomes and Cancer, 2016
- BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axisMedical Oncology, 2015
- BUB1 and BUBR1: multifaceted kinases of the cell cycleTrends in Biochemical Sciences, 2011
- Overexpression of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in gastric cancer—association with tumour cell proliferationThe Journal of Pathology, 2003
- Somatic mutation of thehBUB1 mitotic checkpoint gene in primary lung cancerGenes, Chromosomes and Cancer, 2000